Neuromodulation provides novel treatments by stimulating the body’s nerves to elicit a natural biological response. Find out how China’s contract production facilities lead the world in delivering the manufacturing capabilities this technology demands.
For as long as we’ve understood electricity and nerve function, the idea of harnessing electrical impulses for medical treatment has fascinated scientists. Since the 1960s, they’ve been improving the efficacy of devices based on electrical field stimulation of the brain, spine, and peripheral nerves.
Neuromodulation devices act directly on the body’s nerves. They modulate (change) neural activity by directing electrical energy to a specific location in the body.
There are two broad categories of neuromodulation. The first category, called neurostimulation, directly stimulates nerves to elicit a natural biological response. The other class of treatment releases minute doses of pharmacological compounds at a precise position within the patient’s body.
Neurostimulation devices consist of a power source and a pulse generator. Clinicians precisely place electrodes on the patient’s brain, spinal cord, or peripheral nerves that lead to an implantable pulse generator (IPG).
The generator directs a low-voltage electrical current to the nerve. This current can block pain signals or activate a patient’s absent neural impulses.
This technology allows healthcare professionals to administer micro-doses of potent bioelectric medicine and neurological treatments.
Since the medication doesn’t have to pass through the body or be metabolized, neuromodulation enables physicians to prescribe as little as 1/300th of the usual oral dose of a pharmaceutical product. Micro-doses improve quality of life by reducing side effects and making patients more comfortable.
Neuromodulation is also proving to be a valuable tool for long-term pain management. As the body adjusts over time, pain medications often lose their efficacy, leading to over-medication and opioid dependence when pain increases. Neuromodulation can provide an alternative to patients who may no longer be responding to medication, which in turn can help physicians avoid over-medicating those in need. A long-term cost benefit to the overall healthcare system is also likely, as insurance companies will only have to cover one procedure, with no additional costs attributed to the patient.
Industry watchers are forecasting a compound annual growth rate (CAGR) of 11% for the neuromodulation market over the next five years. The aging population and the corresponding increase in the incidence of neurological disorders are driving this market trend.
The incidence of Parkinson’s Disease, for example, has doubled over the last 25 years, and the prevalence of nerve-related conditions such as epilepsy, depression, spinal cord injuries, and urinary incontinence are all on the rise.
Because neurological diseases among the elderly increase the risk of strokes, headaches, and degenerative diseases like dementia, the medical profession is enthusiastic about new therapies that can improve patient outcomes. In addition, researchers are identifying new indications for the technology and a broader range of target applications.
Pandemic disruptions have also increased interest in neuromodulation. Because neuromodulation is less invasive than other COVID-19 therapies, a growing number of healthcare professionals are prescribing it for the adverse effects of “long covid.”
As neuromodulation gains recognition and is better understood, manufacturers such as Boston Scientific, Medtronic, and St-Jude Medical, among many others, are focusing on developing, getting approval for, and launching new devices to expand their product line. Global research and development continues to identify new potential applications and indications on a regular basis.
One of the challenges in researching and developing new devices is balancing regulatory demands and requirements with time-to-market goals. Medical device OEMs of all sizes have turned to contract manufacturers to navigate this tricky balancing act, allowing them to maintain a focus on research and development, while still producing essential components and accessories quickly and at the highest possible standard.
As an example, contract manufacturers can provide a real advantage in the production of neuromodulation supporting accessories. These can include: cables and plastic enclosures, induction charging systems and implant charger components and positioning belts, device carrying cases, and much more.
For 40 years, Kingstec has worked with China’s leading facilities, building long-lasting partnerships with the best manufacturers of electronic neurostimulation and spinal cord stimulator systems and accessories.
With our expertise and market knowledge, we can manufacture the highest quality cables, charger stands, carrying cases, wearable holders, and more, to help you build a portfolio of neuromodulation accessories that are reliable and successful.
The emerging neuromodulation market offers challenges combined with opportunities for western firms partnering with Chinese contract manufacturers. Kingstec can help your business navigate this non-pharmaceutical approach, providing the advanced manufacturing technology and dependable workforce your company needs.
Call us today to learn how your business can partner with China’s cost-efficient, highly adaptable contract manufacturers to produce your neurostimulation components.
